Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck's anti-PD-1 therapy, KEYTRUDA®, along with chemotherapy.

8 May 2018

Experimental diabetes drugs can make cancer cells vulnerable to chemotherapy agents

Scientists at Dana-Farber Cancer Institute have shown that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents, and they say such combinations should be explored to potentially improve outcomes for cancer patients.

2 Jan 2018

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time.

27 Oct 2017

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

A 14-year randomised trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid. The trial demonstrated no improved disease-free survival with neoadjuvant chemotherapy followed by surgery.

11 Sep 2017

Trial confirms standard three-week dosing of chemotherapy as first line treatment in ovarian cancer

European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid.

4 Sep 2017

FDA approves expanded use of Zykadia for first-line treatment of ALK-positive metastatic NSCLC

Novartis today announced the US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.

27 May 2017

Researchers identify DNA repair deficiency in many types of solid tumors

A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.

18 May 2017

Combination therapy may be effective option for treating some women with ovarian cancer

Researchers have been trying to understand why up to 85 percent of women experience recurrence of high-grade serous ovarian cancer -- the most common subtype of ovarian cancer -- after standard treatment with the chemotherapy drug carboplatin.

2 May 2017

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.

17 Apr 2017

KU researcher reveals possible therapeutic intervention for 'chemobrain' in cancer patients

Findings offered by a University of Kansas researcher, identified as one of 20 'Must See Presenters' at the national meeting of the American Chemical Society in early April, suggest a possible therapeutic intervention for "chemobrain," the cognitive impairment plaguing up to a third of cancer patients following chemotherapy.

12 Apr 2017

Study finds biochemical pathway that triggers regrowth of breast cancer stem cells after chemotherapy

Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

22 Feb 2017

Study addresses cost-effectiveness of checkpoint inhibitors for advanced melanoma in Hong Kong

Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapore.

17 Dec 2016

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

In a new paradigm of breast cancer research, physicians are fast-tracking promising new experimental drugs for further study, while immediately dropping drugs and drug combinations that don't work.

8 Jul 2016

First-line nivolumab promising in advanced NSCLC

Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer.

5 Jul 2016

Tandem myeloablative ASCT consolidation boosts neuroblastoma outcomes

Research presented at the American Society of Clinical Oncology annual conference suggests that consolidation therapy with tandem compared with single myeloablative autologous stem cell transplant can improve outcomes in paediatric patients with high-risk neuroblastoma.

12 Jun 2016

Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo.

9 Jun 2016